93,350 Shares in Inogen, Inc $INGN Purchased by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. bought a new stake in shares of Inogen, Inc (NASDAQ:INGN) during the 2nd quarter, Holdings Channel reports. The fund bought 93,350 shares of the medical technology company’s stock, valued at approximately $602,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in Inogen by 30.1% in the first quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company’s stock worth $4,022,000 after purchasing an additional 130,381 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Inogen during the first quarter valued at $85,000. Goldman Sachs Group Inc. lifted its position in Inogen by 16.9% during the first quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company’s stock valued at $2,026,000 after buying an additional 41,002 shares during the period. Jane Street Group LLC bought a new stake in shares of Inogen during the 1st quarter valued at $463,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Inogen by 7.9% during the 2nd quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company’s stock valued at $4,326,000 after buying an additional 44,860 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.

Inogen Price Performance

Inogen stock opened at $5.61 on Friday. Inogen, Inc has a one year low of $5.34 and a one year high of $9.13. The stock has a market capitalization of $148.89 million, a PE ratio of -6.23 and a beta of 1.55. The business’s fifty day moving average is $6.36 and its 200 day moving average is $6.36.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Thursday, August 6th. The medical technology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Inogen had a negative net margin of 6.94% and a negative return on equity of 13.17%. The firm had revenue of $95.08 million during the quarter, compared to analyst estimates of $95.23 million. As a group, sell-side analysts expect that Inogen, Inc will post -0.74 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Inogen in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.

Insider Buying and Selling

In other news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $6.60, for a total value of $72,190.80. Following the completion of the sale, the executive vice president directly owned 5,039 shares in the company, valued at $33,257.40. This represents a 68.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 2.50% of the company’s stock.

Inogen Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.